Acute Myocardial Infarction

Additional studies are necessary to evaluate the prognostic value of ST2 in conjunction with copeptin and other available biomarkers. Thus, these novel biomarkers needs to be further evaluated in larger prospective and interventional studies to produce better evidence for a routine clinical evaluation of patients suffering from acute myocardial infarction and other cardiovascular diseases. In the Emergency department patients presenting with acute chest pain suggestive of acute myocardial infarction (AMI), the combination of cardiac troponin and copeptin, provide faster exclusion of AMI, yet with very good accuracy. In addition to save money and time ,rapid exclusion of AMI would lead to better management of high risks patients that would hopefully reduce the adverse events related to AMI such as heart failure and death. Early detection of AMI would reduce the mortality and morbidity. These novel markers are not solely used for diagnosing AMI but also used in stratifying risks and prognosis that would determine the therapeutic approach of these patients. Sherpa N, Potential Clinical Application of Novel Cardiac Biomarker (Troponin) and Stress Marker (Copeptin) for the Diagnosis of Acute Myocardial Infarction in the Emergency Department

• Share this page
• 
• 
• 
• 
• 
• 

Last date updated on April, 2024